Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure

Justin L. Grodin, Susanna R. Stevens, Lisa de las Fuentes, Michael Kiernan, Edo Y. Birati, Divya Gupta, Bradley A. Bart, G. Michael Felker, Horng Haur Chen, Javed Butler, Victor G. Dávila-Román, Kenneth B. Margulies, Adrian F. Hernandez, Kevin J. Anstrom, W. H Wilson Tang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Worsening renal function in heart failure may be related to increased venous congestion, decreased cardiac output, or both. Diuretics are universally used in acute decompensated heart failure, but they may be ineffective and may lead to azotemia. We aimed to compare the decongestive properties of a urine output-guided diuretic adjustment and standard therapy for the management of cardiorenal syndrome in acute decompensated heart failure. Methods and Results: Data were pooled from subjects randomized to the stepwise pharmacologic care algorithm (SPCA) in the CARRESS-HF trial and those who developed cardiorenal syndrome (rise in creatinine >0.3 mg/dL) in the DOSE-AHF and ROSE-AHF trials. Patients treated with SPCA (n= 94) were compared with patients treated with standard decongestive therapy (SDT) that included intravenous loop diuretic use (DOSE-AHF and ROSE-AHF; n= 107) at the time of cardiorenal syndrome and followed for net fluid balance, weight loss, and changing renal function. The SPCA group had higher degrees of jugular venous pressure (P < .0001) at the time of cardiorenal syndrome. The group that received SPCA had more weight change (-3.4 ± 5.2 lb) and more net fluid loss (1.705 ± 1.417 L) after 24 hours than the SDT group (-0.8 ± 3.4 lb and 0.892 ± 1.395 L, respectively; P < .001 for both) with a slight improvement in renal function (creatinine change -0.1 ± 0.3 vs 0.0 ± 0.3 mg/dL, respectively; P= .03). Conclusions: Compared with SDT, patients who received an intensification of medication therapy for treating persisting congestion had greater net fluid and weight loss without being associated with renal compromise.

Original languageEnglish (US)
JournalJournal of Cardiac Failure
DOIs
StateAccepted/In press - Apr 5 2015

Fingerprint

Cardio-Renal Syndrome
Heart Failure
Kidney
Diuretics
Weight Loss
Creatinine
Sodium Potassium Chloride Symporter Inhibitors
Azotemia
Social Adjustment
Venous Pressure
Water-Electrolyte Balance
Hyperemia
Therapeutics
Group Psychotherapy
Cardiac Output
Neck
Urine
Weights and Measures

Keywords

  • Acute decompensated heart failure
  • Cardiorenal syndrome
  • Diuretics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Grodin, J. L., Stevens, S. R., de las Fuentes, L., Kiernan, M., Birati, E. Y., Gupta, D., ... Tang, W. H. W. (Accepted/In press). Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2015.07.007

Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. / Grodin, Justin L.; Stevens, Susanna R.; de las Fuentes, Lisa; Kiernan, Michael; Birati, Edo Y.; Gupta, Divya; Bart, Bradley A.; Felker, G. Michael; Chen, Horng Haur; Butler, Javed; Dávila-Román, Victor G.; Margulies, Kenneth B.; Hernandez, Adrian F.; Anstrom, Kevin J.; Tang, W. H Wilson.

In: Journal of Cardiac Failure, 05.04.2015.

Research output: Contribution to journalArticle

Grodin, JL, Stevens, SR, de las Fuentes, L, Kiernan, M, Birati, EY, Gupta, D, Bart, BA, Felker, GM, Chen, HH, Butler, J, Dávila-Román, VG, Margulies, KB, Hernandez, AF, Anstrom, KJ & Tang, WHW 2015, 'Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure', Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2015.07.007
Grodin, Justin L. ; Stevens, Susanna R. ; de las Fuentes, Lisa ; Kiernan, Michael ; Birati, Edo Y. ; Gupta, Divya ; Bart, Bradley A. ; Felker, G. Michael ; Chen, Horng Haur ; Butler, Javed ; Dávila-Román, Victor G. ; Margulies, Kenneth B. ; Hernandez, Adrian F. ; Anstrom, Kevin J. ; Tang, W. H Wilson. / Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. In: Journal of Cardiac Failure. 2015.
@article{6c8e318bdace44bdac29c786499c9078,
title = "Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure",
abstract = "Background: Worsening renal function in heart failure may be related to increased venous congestion, decreased cardiac output, or both. Diuretics are universally used in acute decompensated heart failure, but they may be ineffective and may lead to azotemia. We aimed to compare the decongestive properties of a urine output-guided diuretic adjustment and standard therapy for the management of cardiorenal syndrome in acute decompensated heart failure. Methods and Results: Data were pooled from subjects randomized to the stepwise pharmacologic care algorithm (SPCA) in the CARRESS-HF trial and those who developed cardiorenal syndrome (rise in creatinine >0.3 mg/dL) in the DOSE-AHF and ROSE-AHF trials. Patients treated with SPCA (n= 94) were compared with patients treated with standard decongestive therapy (SDT) that included intravenous loop diuretic use (DOSE-AHF and ROSE-AHF; n= 107) at the time of cardiorenal syndrome and followed for net fluid balance, weight loss, and changing renal function. The SPCA group had higher degrees of jugular venous pressure (P < .0001) at the time of cardiorenal syndrome. The group that received SPCA had more weight change (-3.4 ± 5.2 lb) and more net fluid loss (1.705 ± 1.417 L) after 24 hours than the SDT group (-0.8 ± 3.4 lb and 0.892 ± 1.395 L, respectively; P < .001 for both) with a slight improvement in renal function (creatinine change -0.1 ± 0.3 vs 0.0 ± 0.3 mg/dL, respectively; P= .03). Conclusions: Compared with SDT, patients who received an intensification of medication therapy for treating persisting congestion had greater net fluid and weight loss without being associated with renal compromise.",
keywords = "Acute decompensated heart failure, Cardiorenal syndrome, Diuretics",
author = "Grodin, {Justin L.} and Stevens, {Susanna R.} and {de las Fuentes}, Lisa and Michael Kiernan and Birati, {Edo Y.} and Divya Gupta and Bart, {Bradley A.} and Felker, {G. Michael} and Chen, {Horng Haur} and Javed Butler and D{\'a}vila-Rom{\'a}n, {Victor G.} and Margulies, {Kenneth B.} and Hernandez, {Adrian F.} and Anstrom, {Kevin J.} and Tang, {W. H Wilson}",
year = "2015",
month = "4",
day = "5",
doi = "10.1016/j.cardfail.2015.07.007",
language = "English (US)",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure

AU - Grodin, Justin L.

AU - Stevens, Susanna R.

AU - de las Fuentes, Lisa

AU - Kiernan, Michael

AU - Birati, Edo Y.

AU - Gupta, Divya

AU - Bart, Bradley A.

AU - Felker, G. Michael

AU - Chen, Horng Haur

AU - Butler, Javed

AU - Dávila-Román, Victor G.

AU - Margulies, Kenneth B.

AU - Hernandez, Adrian F.

AU - Anstrom, Kevin J.

AU - Tang, W. H Wilson

PY - 2015/4/5

Y1 - 2015/4/5

N2 - Background: Worsening renal function in heart failure may be related to increased venous congestion, decreased cardiac output, or both. Diuretics are universally used in acute decompensated heart failure, but they may be ineffective and may lead to azotemia. We aimed to compare the decongestive properties of a urine output-guided diuretic adjustment and standard therapy for the management of cardiorenal syndrome in acute decompensated heart failure. Methods and Results: Data were pooled from subjects randomized to the stepwise pharmacologic care algorithm (SPCA) in the CARRESS-HF trial and those who developed cardiorenal syndrome (rise in creatinine >0.3 mg/dL) in the DOSE-AHF and ROSE-AHF trials. Patients treated with SPCA (n= 94) were compared with patients treated with standard decongestive therapy (SDT) that included intravenous loop diuretic use (DOSE-AHF and ROSE-AHF; n= 107) at the time of cardiorenal syndrome and followed for net fluid balance, weight loss, and changing renal function. The SPCA group had higher degrees of jugular venous pressure (P < .0001) at the time of cardiorenal syndrome. The group that received SPCA had more weight change (-3.4 ± 5.2 lb) and more net fluid loss (1.705 ± 1.417 L) after 24 hours than the SDT group (-0.8 ± 3.4 lb and 0.892 ± 1.395 L, respectively; P < .001 for both) with a slight improvement in renal function (creatinine change -0.1 ± 0.3 vs 0.0 ± 0.3 mg/dL, respectively; P= .03). Conclusions: Compared with SDT, patients who received an intensification of medication therapy for treating persisting congestion had greater net fluid and weight loss without being associated with renal compromise.

AB - Background: Worsening renal function in heart failure may be related to increased venous congestion, decreased cardiac output, or both. Diuretics are universally used in acute decompensated heart failure, but they may be ineffective and may lead to azotemia. We aimed to compare the decongestive properties of a urine output-guided diuretic adjustment and standard therapy for the management of cardiorenal syndrome in acute decompensated heart failure. Methods and Results: Data were pooled from subjects randomized to the stepwise pharmacologic care algorithm (SPCA) in the CARRESS-HF trial and those who developed cardiorenal syndrome (rise in creatinine >0.3 mg/dL) in the DOSE-AHF and ROSE-AHF trials. Patients treated with SPCA (n= 94) were compared with patients treated with standard decongestive therapy (SDT) that included intravenous loop diuretic use (DOSE-AHF and ROSE-AHF; n= 107) at the time of cardiorenal syndrome and followed for net fluid balance, weight loss, and changing renal function. The SPCA group had higher degrees of jugular venous pressure (P < .0001) at the time of cardiorenal syndrome. The group that received SPCA had more weight change (-3.4 ± 5.2 lb) and more net fluid loss (1.705 ± 1.417 L) after 24 hours than the SDT group (-0.8 ± 3.4 lb and 0.892 ± 1.395 L, respectively; P < .001 for both) with a slight improvement in renal function (creatinine change -0.1 ± 0.3 vs 0.0 ± 0.3 mg/dL, respectively; P= .03). Conclusions: Compared with SDT, patients who received an intensification of medication therapy for treating persisting congestion had greater net fluid and weight loss without being associated with renal compromise.

KW - Acute decompensated heart failure

KW - Cardiorenal syndrome

KW - Diuretics

UR - http://www.scopus.com/inward/record.url?scp=84939183527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939183527&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2015.07.007

DO - 10.1016/j.cardfail.2015.07.007

M3 - Article

C2 - 26209004

AN - SCOPUS:84939183527

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

ER -